Opinion

Video

FDA Approves Sotatercept for Pulmonary Arterial Hypertension

Author(s):

Marius Hoeper, MD

Marius Hoeper, MD, offers expert perspectives on the recently FDA-approved sotatercept, focusing on its mechanism of action, potential cost implications, and potential advantages and disadvantages it could offer compared with existing foundational therapies.

Video content above is prompted by the following question(s):

  • What is the mechanism of action for the recent FDA-approved drug sotatercept and how does it differ from existing pulmonary arterial hypertension (PAH) therapies?
  • Given that sotatercept is currently approved as an add-on therapy, what potential cost implications should payers and health systems consider?
  • Is sotatercept being studied as a foundational therapy for PAH? If so, what potential advantages or disadvantages could it offer compared to existing foundational therapies?
Related Videos
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Susan Perlman, MD, an expert on Friedreich's ataxia
Related Content
Doctor with hands holding an image of lungs | Image credit: Orawan - stock.adobe.com
November 20th 2024

Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed

Gayle Turim Dickstein
Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Patients with PAH may experience issues with sleep | image credit: princeoflove - stock.adobe.com
November 14th 2024

Poor Sleep Quality Associated With Pulmonary Arterial Hypertension

Karen Jacobson-Sive
Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant predictor of sleep quality, independent of disease severity, according to this study.
patient and doctor - Halfpoint - stock.adobe.com.jpeg
November 6th 2024

Refinements to European Strategy Can Improve PAH-CHD Stratification

AJMC Contributor
When patients were re-classified based on the adjusted thresholds of N-terminal pro-brain natriuretic peptide and 6-minute walk distance and the inclusion of TAPSE rather than right atria area, classification of patients improved significantly.
Pulmonary hypertension | Image Credit: © Designpics - stock.adobe.com
November 1st 2024

PAH Treatment Outcomes Similar Regardless of Diagnosis Time

AJMC Contributor
The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
PAH concept | image credit: Ahmad - stock.adobe.com
October 23rd 2024

Early Use of Triple Oral Therapy May Lower Hospitalizations for PAH

AJMC Contributor
The comparative effectiveness study found that the addition of selexipag (Uptravi) to double oral therapy (DOT) reduced the risk of patients being hospitalized or having their disease progress.
Doctor holds lung model representing PAH | Image Credit: © Orawan - stock.adobe.com
October 16th 2024

Certain Immune Cells May Increase, Decrease PAH Risk

Gayle Turim Dickstein
Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo